Primary prostate cancer educates bone stroma through exosomal pyruvate kinase M2 to promote bone metastasis

被引:138
作者
Dai, Jinlu [1 ]
Escara-Wilke, June [1 ]
Keller, Jill M. [1 ,2 ]
Jung, Younghun [3 ]
Taichman, Russell [3 ]
Pienta, Kenneth J. [4 ]
Keller, Evan T. [1 ,2 ,5 ]
机构
[1] Univ Michigan, Sch Med, Dept Urol, Ann Arbor, MI 48109 USA
[2] Univ Michigan, Unit Lab Anim Med, Ann Arbor, MI 48109 USA
[3] Univ Michigan, Sch Dent, Periodont & Oral Med, Ann Arbor, MI 48109 USA
[4] Johns Hopkins Univ, Brady Urol Inst, Dept Urol, Baltimore, MD USA
[5] Univ Michigan, Biointerfaces Inst, Ann Arbor, MI 48109 USA
基金
美国国家卫生研究院;
关键词
EXPRESSION; CELLS; PKM2; MICROENVIRONMENT; PATHWAY; SWITCH;
D O I
10.1084/jem.20190158
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Prostate cancer (PCa) metastasizes selectively to bone through unknown mechanisms. In the current study, we identified exosome-mediated transfer of pyruvate kinase M2 (PKM2) from PCa cells into bone marrow stromal cells (BMSCs) as a novel mechanism through which primary tumor-derived exosomes promote premetastatic niche formation. We found that PKM2 up-regulates BMSC CXCL12 production in a HIF-1 alpha-dependent fashion, which subsequently enhances PCa seeding and growth in the bone marrow. Furthermore, serum-derived exosomes from patients with either primary PCa or PCa metastasis, as opposed to healthy men, reveal that increased exosome PKM2 expression is associated with metastasis, suggesting clinical relevance of exosome PKM2 in PCa. Targeting the exosome-induced CXCL12 axis diminished exosome-mediated bone metastasis. In summary, primary PCa cells educate the bone marrow to create a premetastatic niche through primary PCa exosome-mediated transfer of PKM2 into BMSCs and subsequent up-regulation of CXCL12. This novel mechanism indicates the potential for exosome PKM2 as a biomarker and suggests therapeutic targets for PCa bone metastasis.
引用
收藏
页码:2883 / 2899
页数:17
相关论文
共 50 条
  • [21] Tumor-derived exosomal miR-934 induces macrophage M2 polarization to promote liver metastasis of colorectal cancer
    Zhao, Senlin
    Mi, Yushuai
    Guan, Bingjie
    Zheng, Binbin
    Wei, Ping
    Gu, Yanzi
    Zhang, Zhengxiang
    Cai, Sanjun
    Xu, Ye
    Li, Xinxiang
    He, Xuefeng
    Zhong, Xinyang
    Li, Guichao
    Chen, Zhiyu
    Li, Dawei
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2020, 13 (01)
  • [22] Exosomal αvβ6 integrin is required for monocyte M2 polarization in prostate cancer
    Lu, Huimin
    Bowler, Nicholas
    Harshyne, Larry A.
    Hooper, D. Craig
    Krishn, Shiv Ram
    Kurtoglu, Senem
    Fedele, Carmine
    Liu, Qin
    Tang, Hsin-Yao
    Kossenkov, Andrew, V
    Kelly, William K.
    Wang, Kerith
    Kean, Rhonda B.
    Weinreb, Paul H.
    Yu, Lei
    Dutta, Anindita
    Fortina, Paolo
    Ertel, Adam
    Stanczak, Maria
    Forsberg, Flemming
    Gabrilovich, Dmitry, I
    Speicher, David W.
    Altieri, Dario C.
    Languino, Lucia R.
    MATRIX BIOLOGY, 2018, 70 : 20 - 35
  • [23] Targeting Pyruvate Kinase M2 and Lactate Dehydrogenase A Is an Effective Combination Strategy for the Treatment of Pancreatic Cancer
    Mohammad, Goran Hamid
    Vassileva, Vessela
    Acedo, Pilar
    Damink, Steven W. M. Olde
    Malago, Massimo
    Dhar, Dipok Kumar
    Pereira, Stephen P.
    CANCERS, 2019, 11 (09)
  • [24] Potential adverse effects to the retina of cancer therapy targeting pyruvate kinase M2
    Ng, Soo Khai
    Wood, John P. M.
    Chidlow, Glyn
    Peet, Daniel J.
    Casson, Robert J.
    ACTA ONCOLOGICA, 2015, 54 (01) : 136 - 137
  • [25] The Clinicopathological and Prognostic Relevance of Pyruvate Kinase M2 and pAkt Expression in Breast Cancer
    Benesch, Carina
    Schneider, Christine
    Voelker, Hans-Ullrich
    Kapp, Michaela
    Caffier, Hans
    Krockenberger, Mathias
    Dietl, Johannes
    Kammerer, Ulrike
    Schmidt, Melanie
    ANTICANCER RESEARCH, 2010, 30 (05) : 1689 - 1694
  • [26] Non-metabolic enzyme function of pyruvate kinase M2 in breast cancer
    Jemal, Mohammed
    Getinet, Mamaru
    Amare, Gashaw Azanaw
    Tegegne, Bantayehu Addis
    Baylie, Temesgen
    Mengistu, Enyew Fenta
    Osman, Enatnesh Essa
    Waritu, Nuredin Chura
    Adugna, Adane
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [27] Apatinib weakens proliferation, migration, invasion, and angiogenesis of thyroid cancer cells through downregulating pyruvate kinase M2
    Yang, Xia
    Li, Wenhong
    Han, Xiaoying
    Wang, Jiao
    Dai, Jianjian
    Ye, Xin
    Meng, Min
    SCIENTIFIC REPORTS, 2024, 14 (01)
  • [28] Leptin promotes epithelial-mesenchymal transition of breast cancer via the upregulation of pyruvate kinase M2
    Wei, Lan
    Li, Kuangfa
    Pang, Xueli
    Guo, Bianqin
    Su, Min
    Huang, Yunxiu
    Wang, Nian
    Ji, Feihu
    Zhong, Changli
    Yang, Junhong
    Zhang, Zhiqian
    Jiang, Yulin
    Liu, Yifeng
    Chen, Tingmei
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2016, 35
  • [29] Pyruvate kinase M2 is a novel diagnostic marker and predicts tumor progression in human biliary tract cancer
    Dhar, Dipok Kumar
    Damink, Steven W. M. Olde
    Brindley, James Hal
    Godfrey, Andrew
    Chapman, Michael H.
    Sandanayake, Neomal S.
    Andreola, Fausto
    Mazurek, Sybille
    Hasan, Tayyaba
    Malago, Massimo
    Pereira, Stephen P.
    CANCER, 2013, 119 (03) : 575 - 585
  • [30] miR-181b/Oncostatin m axis inhibits prostate cancer bone metastasis via modulating osteoclast differentiation
    Han, Ziwei
    Zhan, Ruisen
    Chen, Shijie
    Deng, Jia
    Shi, Jian
    Wang, Weiguo
    JOURNAL OF CELLULAR BIOCHEMISTRY, 2020, 121 (02) : 1664 - 1674